Mölnlycke integrated Annual Report 2023
Today we are delighted to announce the launch of the Mölnlycke integrated Annual Report 2023. Our dedication to revolutionising care for people and planet contributed to a very successful year with record high annual net sales of EUR 1,924 million and substantial improvements in profitability. We continue to report our sustainability achievements in accordance with the Global Reporting Initiative (GRI) standards.

Performance highlights
Mölnlycke reported strong growth in 2023, with net sales reaching EUR 1,924 million, an 8% increase in constant currency rates. The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic growth and market share gains across most markets.
Sustainability achievements
We made significant strides in operationalising our sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission reduction targets were validated by the Science Based Targets initiative. Noteworthy progress was made in our journey towards 100% fossil-free electricity by the end of 2024, with 61% fossil-free electricity share in 2023. We also achieved a 20% reduction in overall absolute greenhouse gas emissions across the entire value chain compared to the 2021 baseline. Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our portfolio in terms of net sales.

"2023년에도 우리는 고객 조사에 확고하게 뿌리를 둔 전략을 계속 실행했으며 지속 가능한 디지털 및 고객 중심 의료 서비스를 선도하기 위해 선회했습니다. 강력한 성장과 수익성의 상당한 개선으로 우리가 올바른 길을 가고 있다고 확신합니다."
즐라트코 리흐테르 최고경영자(CEO)
Innovation and quality highlights
To enhance surgical performance, Mölnlycke introduced hand scanning technology using artificial intelligence and machine learning for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex® Border Post-Op product family globally and registered Hibiwash®, - the new colour- and fragrance-free Hibi formula. We also successfully completed the transition to Medical Device Regulation (MDR), one of the first MedTech companies to do so.
Strategic investments
Mölnlycke secured long-term financing through a EUR 400 million Eurobond and a EUR 350 million Revolving Credit Facility. We also decided to invest EUR 60 million to increase production capacity, including a new Mepilex Border Flex production line and a new Ethylene Oxide sterilisation unit in Finland.
Latest news
-
Mölnlycke improves overall score in 2026 EcoVadis sustainability assessment
Mölnlycke has further strengthened its sustainability performance in the latest EcoVadis assessment, achieving a ranking in the 98th percentile.
-
Dartford and Gravesham NHS Trust adopts Steriwave to support infection prevention
Dartford and Gravesham NHS Trust in the UK has adopted Steriwave® nasal photodisinfection for elective orthopaedic surgery, working with Mölnlycke and Ondine Biomedical to strengthen its approach to surgical site infection prevention.
-
New leaders appointed for Mölnlycke Health Care
Gothenburg, Sweden. 3 November 2026. Mölnlycke® announces the appointment of Anders Andersson as Chief Executive Officer (CEO) of Mölnlycke Health Care and Fredrik Wallefors as President of Surgical, effective 1 January 2027.
-
Mölnlycke Health Care announces new partnership with DEBRA International to help advance wound care for the EB community
Mölnlycke is partnering with DEBRA International, the world’s leading epidermolysis bullosa (EB) patient advocacy network, to deepen understanding of the needs of people living with EB and help advance wound care for the global EB community.
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold strategic partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.